EDF Ventures
VC Fund
Ann Arbor, United States
EDF Ventures is a leading venture capital firm investing in early-stage healthcare companies.
- Total investments:
- 49
- Last investment:
- Lead investor:
- 8%
- Fund size:
- $2.5M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries EDF Ventures invests in
Stages EDF Ventures invests in
Countries EDF Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 10 (20%)
- Biotechnology 8 (16%)
- Medical Device 7 (14%)
- Manufacturing 5 (10%)
- Information Technology 5 (10%)
Stage
- Series B 13 (27%)
- Series A 10 (20%)
- Series C 9 (18%)
- Funding Round 9 (18%)
- Series D 4 (8%)
Country
- United States 27 (55%)
- France 2 (4%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Mary Lincoln Campbell
Managing Director
|
Managing Director | Total investments: 3 | Find email | |
Jim Adox
Team Member
|
Team Member | Total investments: 20 | Find email | |
Mary Campbell
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Mike DeVries
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
Mike DeVries
Managing Director
|
Managing Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BeZero Carbon
|
BeZero Carbon is here to build markets and environmental assets, starting with the Voluntary Carbon Market. | $50M / Series B / Nov 14, 2022 | |
DataBank
|
DataBank is a leading information management and security company, offering customized technology solutions designed to help organizations manage risk and improve their business performance. | $1.5B / Secondary Market / Aug 30, 2022 | |
IntelePeer
|
We enable companies to communicate better – driving more revenue, improving their customer experience, and making better business decisions – leveraging omni-channel Automation & Self-Service, AI, and Analytics, all delivered through a single easy-to-use cloud platform that works seamlessly with your existing business solutions. | $15M / Series D / Jun 10, 2013 | |
Direct Flow Medical
|
Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgicallytreated each year. | $284K / Apr 01, 2012 | |
TransCorp Spine
|
TransCorp Spine manufactures medical devices and procedures to restore spinal function and preserve healthy tissue. Its product includes SpinePort, a MIS access system. David Lowry, Des O'Farrell, and Scott Tuinstra founded TransCorp Spine in 2008. It has its headquarters in Byron Center in Michigan. | $755K / Series A / May 12, 2011 | |
Sonoma Orthopedics
|
Sonoma Orthopedic Products designs, develops, and delivers proprietary orthopedic implants for physicians to address problematic fractures. The WaviBodyâ„¢ technology platform allows for quick, minimally invasive surgical solutions for active patients. Direct to Bone...Back To Life. | $22M / Series D / Feb 14, 2011 | |
Abionyx Pharma
|
ABIONYX Pharma is a biotech company discovering and developing innovative therapies for patients without existing or effective treatment. | $54.9M / Series C / Jul 25, 2010 | |
|
Direct Flow Medical
|
Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgicallytreated each year. | $40M / Series C / Oct 05, 2009 | |
ValenTx
|
ValenTx is a development-stage medical device company that focuses on minimally-invasive methods for the treatment of morbid obesity. The company was founded in 2002 and headquartered in Maple Grove, Minnesota. | $22M / Series B / Sep 08, 2009 | |
Lycera
|
Lycera is a preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease Lycera's first-in-class drugs are designed to treat immune disorders. The company's technology platforms include proprietary small molecules that modulatea target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway.Drugs that emerge from the Lycera pipeline will represent first-in-class agents that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents. | $36M / Series A / May 05, 2009 | |
| See all 49 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does EDF Ventures invest in?
EDF Ventures invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series A stage. Most of the 49 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact EDF Ventures?
Public channels for EDF Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at EDF Ventures?
The team at EDF Ventures includes Mary Lincoln Campbell (Managing Director), Jim Adox (Team Member) and Mary Campbell (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
